New cancer cases will grow 30% by 2020, with global economic impact exceeding $300 billion
The number of new cancer cases globally will climb to almost 17 million in 2020 from just under 13m today as the population ages and the disease cuts an ever-wider path through emerging economies, according to a new report from the Economist Intelligence Unit and commissioned by LIVESTRONG, an initiative of the Lance Armstrong Foundation (LAF), with the support of the American Cancer Society. Cancer, the second-largest cause of death globally, already imposes a substantial burden on the world economy: medical and related non-medical costs associated with new cancer cases in 2009 were estimated to be $217 billion, the report shows. Lost productivity as a result of time out of work accounts for an additional $69 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze